Clinical Trial: Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Autologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron Disease

Brief Summary: Herein, the investigators study the safety and efficacy of transplanting purified autologous bone marrow-derived stem cells transplanted via the intrathecal route by interventional radiology and the intravenous route.

Detailed Summary:

A motor neuron disease (MND) is any of several neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body. They include amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP) and pseudobulbar palsy; spinal muscular atrophies are also sometimes included in the group.They are neurodegenerative diseases that cause increasing disability and eventually, death.

In spite of intensive research, motor neuron diseases (MNDs) are still incurable. Some of the key factors in this failure to find a cure have been the lack of human cell-based disease models for molecular analysis and drug screening and the difficulty of obtaining homogeneous populations of specific cell types for clinical applications. Stem cell biology has the potential to transform our understanding of disease processes and to revolutionize our approach to develop novel therapies for MNDs.

In this study, the investigators suggest a protocol for the treatment of MND by transplantation of purified autologous bone marrow-derived stem cells via the intrathecal and intravenous route.


Sponsor: Stem Cells Arabia

Current Primary Outcome: Changes in Functional Rating Scale - via questionnaire [ Time Frame: 6 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Change in Appel Scale [ Time Frame: 4 months ]
  • Change in SF-36 (The Short Form (36) Health Survey is a 36 Item) [ Time Frame: 4 months ]
  • Change in Forced Vital Capacity (FVC) [ Time Frame: 4 months ]


Original Secondary Outcome: Same as current

Information By: Stem Cells Arabia

Dates:
Date Received: February 25, 2017
Date Started: September 2016
Date Completion: August 2019
Last Updated: March 1, 2017
Last Verified: November 2016